102
Participants
Start Date
November 1, 2022
Primary Completion Date
November 1, 2025
Study Completion Date
November 1, 2027
Doxorubicin+Ifosfamide+Anlotinib(AI+A)
Doxorubicin（PLD） 40mg/㎡ d1, Ifosfamide（I） 1g/㎡ d1-5, Anlotinib（A）10mg d1-14 Q3weeks \* 3 Circles
Radical Surgery
Radical sarcoma resectional surgery
Beijing Friendship Hospital, Beijing
Peking University First Hospital, Beijing
The Affiliated Hospital of Qingdao University, Qingdao
Shanghai Cancer Hospital, Minhang Branch, Shanghai
Shanghai Zhongshan Hospital, Shanghai
First Affiliated Hospital Xi'an Jiaotong University, Xi’an
Shanghai Zhongshan Hospital
OTHER
The Affiliated Hospital of Qingdao University
OTHER
Peking University First Hospital
OTHER
Shanghai Cancer Hospital, China
OTHER
First Affiliated Hospital Xi'an Jiaotong University
OTHER
Beijing Friendship Hospital
OTHER
Peking University International Hospital
OTHER